Genmab — Juli 2013

[Solsen]

Var det ikke orr der var en smule dårligere og derfor af mindre betydning

[JørgenVarnæs]

jeg mener bestemt, at det var pfs. Det stod vistnok på side 54, men nu kan jeg ikke genfinde rapporten

[Sukkeralf]

Det var ORR der var dårligere - en del dårligere så vidt jeg husker ! Ville egentlig have skrevet til Rachel for en kommentar, men det glemte jeg.

[JørgenVarnæs]

Du har ret sukker - Summary / Conclusion:These results show that with the only exception of the ORR
(lower in this study) all endpoints (PFS, OS) and safety profile in CLL patients treated with ofatumumab in daily practice are consistent with those observed in phase II
and III clinical trials.

[JørgenVarnæs]

står på side 47 i denne rapport: http://www.haematologica.org/content/98/supplement_1/1.full.pdf

[JørgenVarnæs]

orr er 23%

[Sukkeralf]

Mener den var i 40´erne før, men er ikke sikker - fik som sagt aldrig helt checket op på det

[JørgenVarnæs]

jep - godkendelsen var baseret på ORR=42% - http://www.hematology.org/News/2009/4384.aspx

[gentogen]

(bloodjournal.hematologylibrary.org)

[Solsen]

http://finance.yahoo.com/q?s=GNMSF 50.000 stk
omsat

[gentogen]

Martin Schultz: First in Human Protocol for the Compound HuMax-TF-ADC, Master's project, June 2013, Faculty of Health and Medical Sciences, University of Copenhagen.

[gentogen]

Også lidt her (dog ikke ny): Se under David Satijn ved at scrolle ned: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502230/

[JørgenVarnæs]

tak for den Gen - du er en ørn til at finde info omkring GEN!

[gentogen]

Intas launches Mabtas, a biosimilar version of Rituximab May 02, 2013
Ÿ Intas Pharmaceuticals Ltd. has launched Mabtas, a biosimilar version of Rituximab competent in
treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B
cells like Chronic Lymphocytic Leukaemia (CLL) and Rheumatoid Arthritis apart from Non-Hodgkin's
Lymphoma (NHL) in India. With a view to make NHL treatment cost-effective, Mabtas is manufactured

[gentogen]

in the state of the art, Asia's only EU GMP facility of Intas Biopharmaceuticals, Ahmedabad.

[JørgenVarnæs]

er det ikke den første generiske?

[gentogen]

Ofatumumab: http://bloodjournal.hematologylibrary.org/content/122/4/469.full

[gentogen]

Ofatumumab:

[gentogen]

Just a moment...

(jco.ascopubs.org)

[JørgenVarnæs]

Har vi set disse resultater med den her detaljereingsgrad tidligere? Thenote postede dem på den anden kanal: http://files.shareholder.com/downloads/AMDA-KPIBN/2404168726x0x671053/739F7EB2-25B7-4C78-8DE8-FD47AB6CEE82/2013_EHA_Dara_150613.pdf